Page 95 - Read Online

Page 294 Schwarzenbach et al. Cancer Drug Resist 2019;2:271-96 I http://dx.doi.org/10.20517/cdr.2019.010

DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805-10.
104. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene
reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009;113:6411-8.
105. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, et al. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 2015;13:393-401.
106. Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, et al. DNA methylation of miR-7 is a mechanism involved in platinum
response through MAFG overexpression in cancer cells. Theranostics 2017;7:4118-34.
107. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer
2010;17:F19-36.
108. Cai J, Yang C, Yang Q, Ding H, Jia J, et al. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to
cisplatin. Oncogenesis 2013;2:e75.
109. Xiao M, Cai J, Cai L, Jia J, Xie L, et al. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand
break repair. J Ovarian Res 2017;10:24.
110. Zhao HM, Wei W, Sun YH, Gao JH, Wang Q, et al. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in
primary epithelial ovarian cancer cells. Tumour Biol 2015;36:6867-73.
111. Sun C, Li N, Yang Z, Zhou B, He Y, et al. MiR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
J Natl Cancer Inst 2013;105:1750-8.
112. Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, et al. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance
in ovarian cancer cells. Gynecol Oncol 2015;137:143-51.
113. Jin AH, Wei ZL. Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression.
Int J Clin Exp Med 2015;8:13329-34.
114. Samuel P, Pink RC, Caley DP, Currie JM, Brooks SA, Carter DR. Over-expression of miR-31 or loss of KCNMA1 leads to increased
cisplatin resistance in ovarian cancer cells. Tumour Biol 2016;37:2565-73.
115. Lv T, Song K, Zhang L, Li W, Chen Y, et al. MiRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting
HDAC1. Biochem Cell Biol 2018;96:663-71.
116. Li B, Chen H, Wu N, Zhang WJ, Shang LX. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol
Cancer 2014;24:1381-8.
117. Yang C, Cai J, Wang Q, Tang H, Cao J, et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug
resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012;124:325-34.
118. Zhao H, Liu S, Wang G, Wu X, Ding Y, et al. Expression of miR-136 is associated with the primary cisplatin resistance of human
epithelial ovarian cancer. Oncol Rep 2015;33:591-8.
119. Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, et al. Novel circulating microRNA signature as a potential non-invasive multi-
marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 2014;8:874-83.
120. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, et al. MicroRNAs derived from circulating exosomes as noninvasive
biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 2013;8:1156-62.
121. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res
Notes 2012;5:164.
122. Jiang Y, Jiang J, Jia H, Qiao Z, Zhang J. Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun. Cell
Physiol Biochem 2018;51:129-41.
123. Fabrizio FP, Sparaneo A, Trombetta D, Muscarella LA. Epigenetic versus genetic deregulation of the KEAP1/NRF2 axis in solid
tumors: focus on methylation and noncoding RNAs. Oxid Med Cell Longev 2018;2018:2492063.
124. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, et al. MiR-141 regulates KEAP1 and modulates cisplatin
sensitivity in ovarian cancer cells. Oncogene 2013;32:4284-93.
125. Deng Y, Zhao F, Hui L, Li X, Zhang D, et al. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness
and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ovarian Res 2017;10:50.
126. Zhao H, Bi T, Qu Z, Jiang J, Cui S, et al. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian
papillary serous carcinoma. Oncol Rep 2014;32:1003-12.
127. Zhou Y, Chen Q, Qin R, Zhang K, Li H. MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via
downregulation of NOTCH1 in ovarian cancer cells. Tumour Biol 2014;35:12369-78.
128. Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, et al. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian
carcinoma cells. Toxicol Appl Pharmacol 2016;310:9-19.
129. Chen W, Zeng W, Li X, Xiong W, Zhang M, et al. MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to
cisplatin-induced apoptosis. Pharmacogenomics 2016;17:187-97.
130. Chen W, Du J, Li X, Su J, Huang Y, et al. MiR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation
of anti-apoptotic genes. Pharmacogenomics 2017;18:1671-82.
131. Niu L, Ni H, Hou Y, Du Q, Li H. MiR-509-3p enhances platinum drug sensitivity in ovarian cancer. Gene 2019;686:63-7.
132. Zhang J, Liu L, Sun Y, Xiang J, Zhou D, et al. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via
DAPK2 repression. Oncotarget 2016;7:26516-34.
133. Ottevanger PB. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol 2017;44:67-71.
134. Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, et al. Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell
proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol 2016;33:126.